Last updated: 11/03/2018 10:57:48
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Treatment with Pazopanib for Neoadjuvant Breast Cancer
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: A Phase II Clinical Trial of Four Cycles of Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Given Concurrently with Pazopanib as Neoadjuvant Therapy Followed by Postoperative Pazopanib for Women with Locally Advanced Breast Cancer
Trial description: The purpose of this study is to determine whether the treatment of a doxorubicin in combination with cyclophosphamide followed by a combination of pazopanib in combination with paclitaxel prior to surgery results in a pathological complete response in females with breast cancer.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Number of participants with pathologic complete response (pCR) in the breast and nodes
Timeframe: From the start of the study until the time of surgery (average of 221.9 days [standard deviation of 23.65 days] after study entry)
Secondary outcomes:
Number of participants with pathologic complete response (pCR) in the breast
Timeframe: From the start of the study until the time of surgery (average of 221.9 [standard deviation of 23.65 days] days after study entry)
Number of participants with clinical complete response (cCR) in the breast and nodes at the completion of the doxorubicin and cyclophosphamide (AC) period
Timeframe: From the start of the study until an average of 86.2 days (standard deviation of 5.76 days) after study entry
Number of participants with clinical CR (cCR) in the breast and nodes at the completion of the AC and weekly paclitaxel (WP) + pazopanib preoperative periods
Timeframe: From the start of the study until the preoperative evaluation (an average of 203.0 days [standard deviation of 23.19 days] after study entry)
Invasive Recurrence-free Interval (IRFI)
Timeframe: up to 24 months after study entry
Number of participants with cardiac toxicity (per Common Terminology Criteria for Adverse Events Version 3) at the completion of the AC period
Timeframe: From the start of the study until the preoperative evaluation (an average of 86.2 days [standard deviation of 5.76 days] after study entry)
Number of participants with cardiac toxicity (per CTCAE Version 3) at the completion of the AC and weekly paclitaxel (WP) + pazopanib preoperative periods
Timeframe: From the start of the study until the preoperative evaluation (an average of 203.0 days [standard deviation of 23.19 days] after study entry).
Number of participants with cardiac toxicity (per CTCAE Version 3.0) during the postoperative pazopanib period
Timeframe: From the start of the study until the end of the postoperative pazopanib period, which coincides with the start of the end of treatment period (an average of 310.8 days [standard deviation of 85.29 days] after study entry)
Participants with normal thyroid stimulating hormone (TSH) levels at baseline who had an elevated TSH level at least once during the study and during the individual study periods
Timeframe: up to 24 months after study entry
Number of participants with the indicated radiotherapy-related complications
Timeframe: up to 24 months after study entry
Number of participants with recurrence events
Timeframe: up to 24 months after study entry
Interventions:
Enrollment:
101
Primary completion date:
2011-27-12
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Neoplasms, Breast
Product
pazopanib
Collaborators
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Study date(s)
July 2009 to April 2013
Type
Interventional
Phase
2
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
No
- The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the study treatment and submission of tumor and blood samples required for the FB-6 correlative science studies
- The ECOG performance status must be 0 or 1
- Tumor that has been determined to be HER2-positive by immunohistochemistry (3+) or by FISH or CISH (positive for gene amplification), or has been determined to be
- HER2-equivocal and the investigator plans to administer trastuzumab or other targeted therapy.
Inclusion and exclusion criteria
Inclusion criteria:
- The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the study treatment and submission of tumor and blood samples required for the FB-6 correlative science studies
- The ECOG performance status must be 0 or 1
- Patients must have the ability to swallow oral medication.
- The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.
- Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then PgR analysis must also be performed. (Patients are eligible with either hormone receptor-positive or hormone receptor-negative tumors.)
- Patients must have clinical stage IIIA, IIIB, or IIIC disease with a mass in the breast or axilla measuring at least 2.0 cm by physical exam, unless the patient has inflammatory breast cancer, in which case measurable disease by physical exam is not required.
- Adequate organ function
- LVEF assessment by 2-D echocardiogram or MUGA scan performed within 3 months prior to study entry must be greater or equal to 50% regardless of the facility's LLN.
- ECG performed within 4 weeks before study entry must demonstrate a QTc interval that is less than or equal to 0.47 seconds.
- The TSH level must be within normal limits for the laboratory.
Exclusion criteria:
- Tumor that has been determined to be HER2-positive by immunohistochemistry (3+) or by FISH or CISH (positive for gene amplification), or has been determined to be HER2-equivocal and the investigator plans to administer trastuzumab or other targeted therapy.
- FNA alone to diagnose the primary breast cancer.
- Excisional biopsy or lumpectomy performed prior to study entry.
- Surgical axillary staging procedure prior to study entry.
- Definitive clinical or radiologic evidence of metastatic disease.
- History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with RT.
- Contralateral invasive breast cancer at any time.
- Non-breast malignancies unless the patient is considered to be disease-free for 5 or more years prior to study entry and is deemed by her physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
- Requirement for chronic use of any of the prohibited medications or substances
- Previous therapy with anthracyclines, taxanes, or pazopanib for any malignancy.
- Treatment including RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry.
- Continued therapy with any hormonal agent such as raloxifene, tamoxifen, or other SERM.
- Any sex hormonal therapy, e.g., birth control pills and ovarian hormone replacement therapy
- History of hepatitis B or C.
- Symptomatic pancreatitis or asymptomatic greater or equal to grade 2 elevation of amylase or lipase as per NCI CTCAE v3.0.
- History of documented pancreatitis.
- Uncontrolled hypertension defined as systolic BP greater than 140 mmHg or diastolic BP greater greater than 90 mmHg, with or without anti-hypertensive medication.
- History of hypertensive crisis or hypertensive encephalopathy.
- Cardiac disease that would preclude the use of any of the drugs included in the FB-6 treatment regimen.
- History of TIA or CVA.
- History of any arterial thrombotic event within 12 months prior to study entry.
- Pulmonary embolism or DVT within 6 months prior to study entry.
- Symptomatic peripheral vascular disease.
- Any significant bleeding within 6 months prior to study entry, exclusive of menorrhagia in premenopausal women.
- Known bleeding diathesis, coagulopathy, or requirement for therapeutic doses of coumadin.
- Serious or non-healing wound, skin ulcers, or bone fracture.
- Gastroduodenal ulcer(s) determined by endoscopy to be active.
- History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
- Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of the stomach or small bowel, or other disease significantly affecting gastrointestinal function.
- Sensory/motor neuropathy greater or equal to grade 2, as defined by the NCI's CTCAE v3.0.
- Conditions that would prohibit intermittent administration of corticosteroids for paclitaxel premedication.
- Anticipation of need for major surgical procedures (other than the required breast surgery) during the course of study therapy and for at least 3 months following the last dose of pazopanib.
- Pregnancy or lactation at the time of study entry.
- Other nonmalignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
- Known immediate or delayed hypersensitivity reaction to doxorubicin, cyclophosphamide, paclitaxel, pazopanib, or drugs chemically related to pazopanib.
- Use of any investigational agent within 4 weeks prior to enrollment in the study.
Trial location(s)
Location
GSK Investigational Site
Saginaw, Michigan, United States, 48601
Status
Study Complete
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Status
Study Complete
Location
GSK Investigational Site
St. Louis Park, Minnesota, United States, 55416
Status
Study Complete
Location
GSK Investigational Site
Colorado Springs, Colorado, United States, 80907
Status
Study Complete
Location
GSK Investigational Site
Brighton, Michigan, United States, 48114
Status
Study Complete
Location
GSK Investigational Site
Denver, Colorado, United States, 80218
Status
Study Complete
Showing 1 - 6 of 143 Results
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
No longer a GSK study
Actual primary completion date
2011-27-12
Actual study completion date
2013-24-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website